Published in Gynecol Oncol on April 01, 1999
Recent advances in granulosa cell tumor ovary: a review. Indian J Surg Oncol (2012) 1.06
A late recurring and easily forgotten tumor: ovarian granulosa cell tumor. World J Surg Oncol (2012) 0.93
Prolonged survival following maximal cytoreductive effort for peritoneal metastases from recurrent granulosa cell tumor of the ovary. J Gynecol Oncol (2011) 0.90
Juvenile granulosa cell tumor of the ovary presenting with pleural effusion and ascites. Int J Clin Oncol (2009) 0.81
GnRH agonist therapy in a patient with recurrent ovarian granulosa cell tumors. J Korean Med Sci (2009) 0.76
Nearly 30 Years of Treatment for Recurrent Granulosa Cell Tumor of the Ovary: A Case Report and Review of the Literature. Case Rep Oncol (2010) 0.76
The role of systemic chemotherapy in the management of granulosa cell tumors. Gynecol Oncol (2014) 0.75
Ovarian Sex Cord-Stromal Tumors. J Oncol Pract (2016) 0.75
Ovarian granulosa cell tumor: clinical features, treatment, outcome, and prognostic factors. N Am J Med Sci (2014) 0.75
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med (1999) 7.56
Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys (1995) 4.26
Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer (2007) 2.71
Ovarian carcinomas with transitional cell carcinoma pattern. Am J Clin Pathol (1990) 2.70
Potential biological effects following high X-ray dose interventional procedures. J Vasc Interv Radiol (1994) 2.67
Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol (2001) 2.05
Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology (2009) 2.00
New mutations associated with resistance not detected following zidovudine monotherapy in pregnancy when used in accordance with British HIV Association guidelines. HIV Med (2008) 1.99
Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol (2000) 1.95
Paget's disease of the vulva: pathology, pattern of involvement, and prognosis. Gynecol Oncol (2000) 1.82
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol (2001) 1.73
Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol (2001) 1.59
Quantification of intracavitary brachytherapy parameters and correlation with outcome in patients with carcinoma of the cervix. Int J Radiat Oncol Biol Phys (2000) 1.58
Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol (1999) 1.56
Primary medical management of recurrent aggressive angiomyxoma of the vulva with a gonadotropin-releasing hormone agonist. Gynecol Oncol (2001) 1.55
Tumor recurrence in stage I ovarian serous neoplasms of low malignant potential. Int J Gynecol Pathol (1998) 1.54
Figo IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int J Radiat Oncol Biol Phys (1999) 1.54
High-dose-rate brachytherapy for carcinoma of the cervix: high tech or high risk? Int J Radiat Oncol Biol Phys (1992) 1.54
Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (1999) 1.53
Prognostic factors in adult granulosa cell tumor of the ovary. Cancer (1997) 1.49
Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration. J Natl Cancer Inst (1991) 1.49
Bulky endocervical carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys (1992) 1.49
The ilvB locus of Escherichia coli K-12 is an operon encoding both subunits of acetohydroxyacid synthase I. Nucleic Acids Res (1985) 1.49
Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol (1994) 1.46
Groin dissection practices among gynecologic oncologists treating early vulvar cancer. Gynecol Oncol (1996) 1.43
Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol (2000) 1.41
The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: "maintenance" therapy reconsidered. Gynecol Oncol (1992) 1.40
Papillary serous carcinoma of the peritoneum. Obstet Gynecol (1990) 1.33
Use of dried whole blood spots for quantification of HIV-1 RNA. AIDS (1999) 1.33
Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study. Gynecol Oncol (1996) 1.33
Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol (1995) 1.29
Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Obstet Gynecol (1996) 1.27
Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol (1989) 1.24
Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med (1986) 1.23
Hemorrhagic cystitis following radiotherapy for stage Ib cancer of the cervix. Gynecol Oncol (1994) 1.18
Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol (2001) 1.17
Biologic course of cervical human papillomavirus infection. Obstet Gynecol (1987) 1.14
Laparoscopic port-site metastases in patients with gynecological malignancies. Int J Gynecol Cancer (2004) 1.13
Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res (2001) 1.11
Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol (1997) 1.11
Standardized histologic grading of epithelial ovarian cancer: elusive after all these years. Gynecol Oncol (1998) 1.10
Sexual dysfunction and treatment for early stage cervical cancer. Cancer (1989) 1.10
Ovarian serous borderline tumors with invasive peritoneal implants. Cancer (1998) 1.10
Retroperitoneal teratoma presenting as an abdominal-pelvic mass. Obstet Gynecol (1987) 1.10
Analysis of the severe complications of irradiation of carcinoma of the cervix: whole pelvis irradiation and intracavitary radium. Int J Radiat Oncol Biol Phys (1983) 1.08
Immature teratoma of the ovary. Obstet Gynecol (1986) 1.07
Sigmoid perforation following radiation therapy in patients with cervical cancer. Gynecol Oncol (2001) 1.07
Intraoperative lymphatic mapping for vulvar cancer. Obstet Gynecol (1994) 1.06
Mixed germ cell tumors of the ovary. Obstet Gynecol (1984) 1.06
A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol (2001) 1.04
Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer (1998) 1.04
Non-Hodgkin's lymphoma involving the vagina: a clinicopathologic analysis of 14 patients. Am J Surg Pathol (2000) 1.04
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol (1996) 1.04
Genotyping of B and non-B subtypes of human immunodeficiency virus type 1. J Clin Microbiol (2005) 1.03
FIGO stage IIIA carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys (1992) 1.03
Evidence for horizontal and not vertical transmission of human herpesvirus 8 in children born to human immunodeficiency virus-infected mothers. Pediatr Infect Dis J (1999) 1.02
Adenocarcinoma of the endometrium: analysis of 256 cases with carcinoma limited to the uterine corpus. Pathology review and analysis of prognostic variables. Gynecol Oncol (1982) 1.02
Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol (1992) 1.01
Recurrent cervical carcinoma after radical hysterectomy. Gynecol Oncol (1988) 1.01
Sp1 activation of a TATA-less promoter requires a species-specific interaction involving transcription factor IID. Nucleic Acids Res (1998) 1.00
Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer (2005) 1.00
Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10. Int J Radiat Oncol Biol Phys (1998) 0.99
Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol (1991) 0.98
Adenoid cystic carcinoma of Bartholin gland. Obstet Gynecol (1986) 0.98
Single-agent cis-platinum therapy for advanced ovarian cancer. Obstet Gynecol (1981) 0.98
Effect of peptide chain length on peptide retention behaviour in reversed-phase chromatography. J Chromatogr (1988) 0.98
Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol (1985) 0.97
Calyceal rupture with perirenal urinoma in a patient with cervical carcinoma. Obstet Gynecol (1987) 0.97
Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol (2001) 0.97
Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Obstet Gynecol (1990) 0.97
Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol (2000) 0.96
Rapidly progressing cervical cancer in a patient with human immunodeficiency virus infection. Gynecol Oncol (1990) 0.96
High-risk metastatic gestational trophoblastic disease. Obstet Gynecol (1985) 0.95
Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design. J Clin Oncol (1998) 0.95
Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer (1985) 0.94
Enterovesical fistula following radiotherapy for gynecologic cancer. Gynecol Oncol (1994) 0.94
Transitional cell carcinoma in high-grade high-stage ovarian carcinoma. An indicator of favorable response to chemotherapy. Cancer (1989) 0.93